

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Garvey et al**

Serial No.: **Not Yet Assigned**

Divisional Application of 09/145,143

Filing Date: **January 5, 2000**

Title: **Nitrosated and Nitrosylated Alpha-Adrenergic Receptor  
Antagonist Compounds, Compositions and Their Uses**

Docket Number: **102258.346**

**ATTN: BOX PATENT APPLICATION**

Assistant Commissioner for Patents

Washington, DC 20231

**TRANSMITTAL LETTER**

Enclosed herewith for filing in the United States Patent and Trademark Office for the above-referenced application are the following documents:

1. United States Divisional Patent Application filed under 37 C.F.R. § 1.53(b) claiming priority to:

- (i) U.S. Application No. 09/145,143, filed September 1, 1998, pending;
- (ii) which is a continuation-in-part of U.S. Application No. 08/714,313, filed September 18, 1996, issued as U.S. Patent No. 5,994,294;
- (iii) which is a continuation-in-part of U.S. Application No. 08/595,732, filed February 2, 1996, issued as U.S. Patent No. 5,932,538;
- (iv) and is a continuation-in-part of PCT/US97/01294, filed January 28, 1997;

naming as inventors: David S. Garvey and Inigo Saenz de Tejada

the application having 96 pages which include:

73 pages of specification;  
15 pages of claims;  
1 page of abstract; and  
7 pages of drawings.

2. Copy of the executed Declaration and Power of Attorney signed by the inventors in parent Application No. 09/145,143;

3. Statement under 37 C.F.R. § 1.63(d)(2).

01/05/00  
jc535 U.S. PTO

jc564 U.S. PTO  
09/478222  
01/05/00

00478222-010500

## Transmittal Letter

Divisional of Application No. 09/145,143

4. Preliminary Amendment;
5. Information Disclosure Statement and four PTO-1449 forms; and
6. Return postcard.

Pursuant to 37 C.F.R. § 1.28(a)(2), Applicants note that small entity status was established in parent Application No. 09/145,143 and small entity status is still proper and desired in the present application.


After entry of the Preliminary Amendment, the fee is calculated as follows:

Claims		Extra Claims	Small Entity Fee per Claim	Small Entity Fee Paid
35 Total	- 20	15	x \$9	\$135
7 Independent	- 3	4	x \$39	\$156

Large Entity Filing Fee	\$380
<b>TOTAL FEE DUE:</b>	<b>\$671</b>

The Commissioner is authorized to charge the fee of **\$671** to Deposit Account No. 08-0219, and to charge any other fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Respectfully submitted,

  
Edward D. Grieff  
Registration No. 38,898

Date: January 5, 2000

HALE and DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004-1008  
Phone: 202-942-8400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Garvey et al**

Serial No.: **Not Yet Assigned**  
Divisional Application of 09/145,143

Filing Date: **January 5, 2000**

Title: **Nitrosated and Nitrosylated Alpha-Adrenergic Receptor  
Antagonist Compounds, Compositions and Their Uses**

Docket Number: **102258.346**

Assistant Commissioner for Patents  
Washington, DC 20231




**STATEMENT UNDER 37 C.F.R. § 1.63(d)(2)**

Pursuant to 37 C.F.R. § 1.63(d)(2), it is requested that Joseph D. Schroeder be deleted as an inventor from the application filed herewith. After entry of the Preliminary Amendment filed concurrently herewith, Joseph D. Schroeder is not an inventor of the claimed subject matter.

Pursuant to 37 C.F.R. § 1.33(b), the undersigned is authorized to delete the name of a person who is not an inventor of the claimed invention in a continuation or divisional application.

Respectfully submitted,

  
Edward D. Grieff  
Registration No. 38,898

Date: January 5, 2000

HALE and DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004-1008  
Phone: 202-942-8400